{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:47:35Z","timestamp":1791809255894,"version":"4.3.4"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>This multicenter retrospective study was conducted to evaluate the 1-year treatment outcome of photodynamic therapy (PDT) combined with anti-vascular endothelial growth factor (VEGF) therapy for pachychoroid neovasculopathy (PNV). A total of 42 eyes of 42 patients with treatment-na\u00efve PNV who were treated with PDT combined with intravitreal injections of an anti-VEGF agent (ranibizumab or aflibercept) for 1 year. All eyes showed exudative and\/or hemorrhagic changes that affected the fovea at baseline. After the initial combination therapy, subfoveal choroidal thickness (SCT) and central retinal thickness (CRT) were significantly reduced and were maintained as such for 12 months (P &lt; 0.01 in SCT and CRT). The best-corrected visual acuity (BCVA) (0.19 \u00b1 0.30 at baseline) significantly improved at 3 months (0.15 \u00b1 0.29, P &lt; 0.05) and further improved at 12 months (0.10 \u00b1 0.30, P &lt; 0.01) when compared to that at baseline. After the initial combination therapy, 32 eyes (76.2%) required no additional treatments for 12 months. The mean number of additional PDT and intravitreal injections of anti-VEGF agents was 0.1 \u00b1 0.3 and 0.9 \u00b1 1.9, respectively. Of the 42 eyes included in this study, 22 eyes (52.4%) had polypoidal lesions at baseline. No significant differences in SCT, CRT, or BCVA were observed at any time points between eyes with and without polypoidal lesions. Of 20 eyes without polypoidal lesions, only 1 eye (5.0%) needed additional treatments. PNV, especially without polypoidal lesions, can be treated effectively with PDT combined with anti-VEGF therapy with few sessions.<\/jats:p>","DOI":"10.1371\/journal.pone.0248760","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T17:37:18Z","timestamp":1616521038000},"page":"e0248760","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1930-3960","authenticated-orcid":true,"given":"Akiko","family":"Miki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sentaro","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Otsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuaki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"pone.0248760.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","article-title":"Pachychoroid neovasculopathy","volume":"35","author":"CE Pang","year":"2015","journal-title":"Retina"},{"key":"pone.0248760.ref002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","article-title":"Pachychoroid disease","volume":"33","author":"CMG Cheung","year":"2019","journal-title":"Eye (Lond)"},{"key":"pone.0248760.ref003","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10384-020-00740-5","article-title":"Pachychoroid disease: a new perspective on exudative maculopathy","volume":"64","author":"Y. Yanagi","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0248760.ref004","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1007\/s10792-020-01522-1","article-title":"Pachychoroid neovasculopathy: a type-1 choroidal neovascularization belonging to the pachychoroid spectrum-pathogenesis, imaging and available treatment options","volume":"40","author":"F Sartini","year":"2020","journal-title":"Int Ophthalmol"},{"key":"pone.0248760.ref005","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1038\/s41598-020-65370-w","article-title":"Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept","volume":"10","author":"B Schworm","year":"2020","journal-title":"Sci Rep"},{"key":"pone.0248760.ref006","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.oret.2019.06.013","article-title":"Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes","volume":"3","author":"M Hata","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"pone.0248760.ref007","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"EVEREST II study group","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"pone.0248760.ref008","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4103\/ijo.IJO_1481_18","article-title":"Treatment outcomes of pachychoroid neovasculopathy with photodynamic therapy and anti-vascular endothelial growth factor","volume":"67","author":"R Roy","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"pone.0248760.ref009","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00417-020-04661-4","article-title":"One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy","volume":"258","author":"Y Kitajima","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"pone.0248760.ref010","first-page":"417","article-title":"Criteria for diagnosis of polypoidal choroidal vasculopathy","volume":"109","author":"Japanese Study Group of Polypoidal Choroidal Vasculopathy","year":"2005","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"pone.0248760.ref011","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bjophthalmol-2018-312275","article-title":"Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept","volume":"103","author":"C Hara","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"pone.0248760.ref012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10384-020-00730-7","article-title":"Features of neovascularization in pachychoroid neovasculopathy compared with type 1 neovascular age-related macular degeneration on optical coherence tomography angiography","volume":"64","author":"S Arf","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0248760.ref013","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10384-020-00773-w","article-title":"Hypothetical pathogenesis of age-related macular degeneration and pachychoroid diseases derived from their genetic characteristics","volume":"64","author":"K Yamashiro","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0248760.ref014","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1167\/iovs.16-20967","article-title":"Intraocular vascular endothelial growth factor levels in Pachychoroid neovasculopathy and neovascular age-related macular degeneration","volume":"58","author":"M Hata","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"pone.0248760.ref015","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/IAE.0b013e31822bf6b1","article-title":"One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy","volume":"31","author":"I Maruko","year":"2011","journal-title":"Retina"},{"key":"pone.0248760.ref016","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/IAE.0000000000000809","article-title":"One-year results of adjunctive photodynamic therapy for type 1 neovascularization associated with thickened choroid","volume":"36","author":"JH Lee","year":"2016","journal-title":"Retina"},{"key":"pone.0248760.ref017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ajo.2010.02.008","article-title":"Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy","volume":"150","author":"F Gomi","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"pone.0248760.ref018","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","article-title":"Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy","volume":"9","author":"BJ Jung","year":"2019","journal-title":"Sci Rep"},{"key":"pone.0248760.ref019","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0002-9394(03)00462-8","article-title":"Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin","volume":"136","author":"WM Chan","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"pone.0248760.ref020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/eye.2016.41","article-title":"Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy","volume":"30","author":"E Smretschnig","year":"2016","journal-title":"Eye"},{"key":"pone.0248760.ref021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10384-020-00722-7","article-title":"One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions","volume":"64","author":"H Matsumoto","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0248760.ref022","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","article-title":"Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy","volume":"38","author":"Y Yanagi","year":"2018","journal-title":"Retina"},{"key":"pone.0248760.ref023","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/IAE.0b013e318156777f","article-title":"Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study","volume":"28","author":"WM Chan","year":"2008","journal-title":"Retina"},{"key":"pone.0248760.ref024","doi-asserted-by":"crossref","first-page":"16204","DOI":"10.1038\/srep16204","article-title":"Pachychoroid neovasculopathy and age-related macular degeneration","volume":"5","author":"M Miyake","year":"2015","journal-title":"Sci Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T17:37:40Z","timestamp":1616521060000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248760"}},"subtitle":[],"editor":[{"given":"M. Elizabeth","family":"Hartnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248760","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]}}}